Profile data is unavailable for this security.
About the company
Pacira BioSciences, Inc. is the holding company for its subsidiary, Pacira Pharmaceuticals, Inc. The Company has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera, a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat largely prevalent diseases like osteoarthritis.
- Revenue in USD (TTM)716.79m
- Net income in USD21.44m
- Incorporated2006
- Employees790.00
- LocationPacira Biosciences Inc2000 SIERRA POINT PARKWAY, SUITE 900BRISBANE 94005United StatesUSA
- Phone+1 (650) 242-8052
- Fax+1 (302) 655-5049
- Websitehttps://www.pacira.com/
More ▼
Mergers & acquisitions
| Acquired company | PCRX:NSQ since announced | Transaction value |
|---|---|---|
| GQ Bio Therapeutics GmbH | -17.58% | 32.00m |
Data delayed at least 15 minutes, as of Feb 06 2026 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Invivyd Inc | 50.04m | -59.86m | 482.20m | 99.00 | -- | 3.94 | -- | 9.64 | -0.4736 | -0.4736 | 0.3778 | 0.4341 | 0.3324 | -- | 5.56 | 505,444.40 | -39.76 | -- | -67.24 | -- | 93.34 | -- | -119.63 | -- | -- | -- | 0.00 | -- | -- | -- | 14.46 | -- | -- | -- |
| Emergent Biosolutions Inc | 788.90m | 75.90m | 553.56m | 900.00 | 8.15 | 0.9536 | 3.18 | 0.7017 | 1.29 | 1.29 | 14.20 | 11.05 | 0.5369 | 1.06 | 5.83 | 876,555.60 | 5.17 | -5.03 | 5.90 | -6.47 | 54.58 | 49.01 | 9.62 | -9.76 | 3.15 | 1.85 | 0.5324 | -- | -0.5432 | -1.15 | 74.94 | -- | -25.06 | -- |
| CorMedix Inc | 214.30m | 162.50m | 579.10m | 64.00 | 3.58 | 1.54 | 3.47 | 2.70 | 2.05 | 2.05 | 2.97 | 4.78 | 0.5174 | 0.8901 | 2.44 | 3,348,495.00 | 39.23 | -42.85 | 48.05 | -49.82 | 92.61 | 91.93 | 75.83 | -327.99 | 1.73 | -- | 0.2802 | -- | -- | 173.65 | 61.31 | -- | 25.91 | -- |
| Rigel Pharmaceuticals Inc | 282.08m | 113.30m | 602.99m | 162.00 | 5.39 | 5.12 | 5.21 | 2.14 | 6.17 | 6.17 | 15.36 | 6.48 | 1.48 | 2.15 | 7.37 | 1,741,210.00 | 59.33 | -16.62 | 97.15 | -28.36 | 93.10 | 95.63 | 40.17 | -16.88 | 2.14 | 25.77 | 0.3368 | -- | 53.38 | 24.77 | 169.69 | -- | -22.92 | -- |
| Sinovac Biotech Ltd | 429.20m | -130.73m | 639.90m | 3.04k | -- | -- | -- | 1.49 | -1.31 | -1.31 | 4.31 | 86.81 | 0.0322 | 0.2019 | 1.08 | 141,325.00 | -2.23 | 36.14 | -3.30 | 58.37 | 92.09 | 90.77 | -69.19 | 65.87 | 11.24 | -- | 0.0262 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
| ASP Isotopes Inc | 8.38m | -105.56m | 652.45m | 136.00 | -- | 6.57 | -- | 77.83 | -1.43 | -1.43 | 0.1124 | 0.7932 | 0.0541 | 8.86 | 0.884 | 61,642.43 | -68.21 | -- | -85.13 | -- | 23.00 | -- | -1,261.23 | -- | 6.10 | -0.6787 | 0.5382 | -- | 857.03 | -- | -115.60 | -- | -- | -- |
| Ironwood Pharmaceuticals, Inc. | 338.99m | 28.55m | 723.92m | 253.00 | 31.69 | -- | 23.77 | 2.14 | 0.1404 | 0.1404 | 2.00 | -1.62 | 0.863 | -- | 3.45 | 1,339,870.00 | 7.27 | -6.08 | 11.57 | -7.13 | -- | -- | 8.42 | -11.01 | -- | 4.73 | 1.82 | -- | -20.63 | -3.89 | 100.09 | -56.87 | -54.38 | -- |
| Esperion Therapeutics Inc | 303.80m | -105.83m | 760.22m | 304.00 | -- | -- | -- | 2.50 | -0.5358 | -0.5358 | 1.54 | -2.20 | 0.896 | 1.35 | 3.25 | 999,348.70 | -31.21 | -61.82 | -138.14 | -101.31 | 58.20 | 81.27 | -34.84 | -109.30 | 0.7017 | -0.3928 | 4.08 | -- | 185.66 | 17.50 | 75.27 | -- | -19.76 | -- |
| Pacira Biosciences Inc | 716.79m | 21.44m | 836.80m | 790.00 | 43.65 | 1.20 | 7.45 | 1.17 | 0.4664 | 0.4664 | 15.70 | 16.93 | 0.5085 | 1.11 | 6.64 | 907,330.40 | 1.52 | 1.87 | 1.78 | 2.22 | 79.17 | 73.06 | 2.99 | 4.84 | 3.78 | -- | 0.3413 | 0.00 | 3.85 | 10.73 | -337.30 | -- | 0.9219 | -- |
| Phathom Pharmaceuticals Inc | 147.19m | -274.55m | 966.96m | 427.00 | -- | -- | -- | 6.57 | -3.81 | -3.81 | 2.04 | -5.95 | 0.4693 | 5.58 | 3.83 | 344,707.30 | -87.53 | -72.89 | -117.10 | -84.11 | 87.25 | -- | -186.53 | -1,799.61 | 2.19 | -3.35 | 3.68 | -- | 8,001.47 | -- | -65.84 | -- | 0.4505 | -- |
| Theravance Biopharma Inc | 80.33m | 29.34m | 992.17m | 97.00 | 34.80 | 4.26 | 32.01 | 12.35 | 0.5626 | 0.5626 | 1.59 | 4.59 | 0.2082 | -- | 4.58 | 828,113.40 | 7.61 | -34.51 | 8.26 | -40.08 | -- | -- | 36.53 | -254.51 | -- | -- | 0.1216 | -- | 12.12 | -2.59 | -2.22 | -- | -36.34 | -- |
| EyePoint Inc | 42.34m | -205.75m | 1.05bn | 165.00 | -- | 4.42 | -- | 24.89 | -2.99 | -2.99 | 0.617 | 2.88 | 0.1532 | 1.02 | 59.51 | 256,606.10 | -74.47 | -35.88 | -86.87 | -42.05 | 94.08 | 84.82 | -485.95 | -201.78 | 7.11 | -- | 0.00 | -- | -5.97 | 16.27 | -84.86 | -- | 80.24 | -- |
| Day One Biopharmaceuticals Inc | 133.67m | -151.76m | 1.08bn | 184.00 | -- | 2.39 | -- | 8.05 | -1.48 | -1.48 | 1.30 | 4.39 | 0.2399 | 2.88 | 10.53 | 738,519.30 | -27.23 | -39.78 | -29.80 | -43.02 | 89.44 | -- | -113.53 | -414.14 | 8.55 | -- | 0.00 | -- | -- | -- | 49.45 | -- | -- | -- |
| Xeris Biopharma Holdings Inc | 266.14m | -15.64m | 1.15bn | 394.00 | -- | -- | -- | 4.31 | -0.1033 | -0.1033 | 1.67 | -0.0052 | 0.77 | 0.7301 | 5.61 | 675,474.60 | -4.52 | -31.61 | -6.46 | -42.28 | 84.56 | 79.76 | -5.88 | -77.77 | 1.35 | 0.3853 | 1.00 | -- | 23.89 | 136.89 | 11.92 | -- | -4.75 | -- |
Data as of Feb 06 2026. Currency figures normalised to Pacira Biosciences Inc's reporting currency: US Dollar USD
61.16%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2025 | 6.38m | 14.84% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 4.42m | 10.28% |
| DOMA Perpetual Capital Management LLCas of 30 Dec 2025 | 2.94m | 6.83% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 2.14m | 4.97% |
| Dimensional Fund Advisors LPas of 30 Sep 2025 | 2.11m | 4.91% |
| D. E. Shaw & Co. LPas of 30 Sep 2025 | 1.94m | 4.51% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 1.90m | 4.42% |
| Balyasny Asset Management LPas of 30 Sep 2025 | 1.89m | 4.38% |
| American Century Investment Management, Inc.as of 30 Sep 2025 | 1.38m | 3.20% |
| Geode Capital Management LLCas of 30 Sep 2025 | 1.22m | 2.83% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
